首页> 美国卫生研究院文献>British Medical Journal >Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
【2h】

Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis

机译:药物或生活方式干预措施可预防或延缓糖耐量异常人群的2型糖尿病:系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective To quantify the effectiveness of pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance. >Data sources Medline, Embase, and the Cochrane library searched up to July 2006. Expert opinions sought and reference lists of identified studies and any relevant published reviews checked. >Study selection Randomised controlled trials that evaluated interventions to delay or prevent type 2 diabetes in individuals with impaired glucose tolerance. >Results 21 trials met the inclusion criteria, of which 17, with 8084 participants with impaired glucose tolerance, reported results in enough detail for inclusion in the meta-analyses. From the meta-analyses the pooled hazard ratios were 0.51 (95% confidence interval 0.44 to 0.60) for lifestyle interventions v standard advice, 0.70 (0.62 to 0.79) for oral diabetes drugs v control, 0.44 (0.28 to 0.69) for orlistat v control, and 0.32 (0.03 to 3.07) for the herbal remedy jiangtang bushen recipe v standard diabetes advice. These correspond to numbers needed to treat for benefit (NNTB) and harm (NNTH) of 6.4 for lifestyle (95% credible interval, NNTB 5.0 to NNTB 8.4), 10.8 for oral diabetes drugs (NNTB 8.1 to NNTB 15.0), 5.4 for orlistat (NNTB 4.1 to NNTB 7.6), and 4.0 for jiangtang bushen (NNTH 16.9 to NNTB 24.8). >Conclusions Lifestyle and pharmacological interventions reduce the rate of progression to type 2 diabetes in people with impaired glucose tolerance. Lifestyle interventions seem to be at least as effective as drug treatment.
机译:>目的,以定量的药物和生活方式干预措施来预防或延迟糖耐量异常患者的2型糖尿病。 >数据来源直到2006年7月,Medline,Embase和Cochrane图书馆都在搜索。寻求专家意见并参考已鉴定研究的参考清单以及任何相关发表的评论。 >研究选择:随机对照试验,评估了糖耐量受损患者延迟或预防2型糖尿病的干预措施。 >结果 21项试验符合纳入标准,其中17项8084名葡萄糖耐量受损的参与者报告了足够详细的结果,可纳入荟萃分析。从荟萃分析中,生活方式干预措施v标准建议的合并风险比为0.51(95%置信区间0.44至0.60),口服糖尿病药物v对照的风险率为0.70(0.62至0.79),奥利司他v对照的风险为0.44(0.28至0.69)。 ,对于草药汤姜补肾食谱v标准糖尿病建议,则为0.32(0.03至3.07)。这些数字对应于生活方式治疗所需的收益(NNTB)和伤害(NNTH)分别为6.4(95%可信区间,NNTB 5.0至NNTB 8.4),口服糖尿病药物为10.8(NNTB 8.1至NNTB 15.0),奥利司他5.4 (NNTB 4.1至NNTB 7.6),以及江塘补肾4.0(NNTH 16.9至NNTB 24.8)。 >结论:生活方式和药理学干预措施可降低糖耐量异常人群中2型糖尿病的发病率。生活方式干预似乎至少与药物治疗一样有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号